Company Immutep Ltd Australian S.E.
Equities
AU000000PRR9
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Deanne Miller
COO | Chief Operating Officer | 47 | 12-10-16 |
Frédéric Triebel
CTO | Chief Tech/Sci/R&D Officer | 69 | 14-12-11 |
Claudia Jacoby
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - | |
Frank Fliegert
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
Frédéric Triebel
CTO | Chief Tech/Sci/R&D Officer | 69 | 14-12-11 |
Pete Meyers
BRD | Director/Board Member | 55 | 14-02-11 |
Lis Boyce
BRD | Director/Board Member | - | 23-04-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,188,834,559 | 1,143,502,554 ( 96.19 %) | 0 | 96.19 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The private company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. |
Biotechnology
|
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |